Internal Medicine, Rheumatology · Thousand Oaks, CA
NPI
1013054865
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
566 Saint Charles Dr
Thousand Oaks, CA, 91360
Phone (805) 449-8781
Groups this clinician bills Medicare through
Medicare paid, 2024
$8.7M
705,420 services
Medicare patients, 2024
1,604
Average age 75
Drug cost, 2024
$4.7M
6,598 prescriptions
Company payments, 2025
$12K
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shariar Cohen-Gadol was code J3111 (injection, romosozumab-aqqg, 1 mg), 215,942 times for 183 patients. In total Shariar Cohen-Gadol billed 705,420 services in 124 codes, and Medicare paid $8.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 215,942 | 183 | $8.56 | $1.8M |
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 179,512 | 65 | $3.62 | $649K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 59,600 | 81 | $9.10 | $542K |
| J3262 Injection, tocilizumab, 1 mg | Office | 53,560 | 17 | $4.71 | $252K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 46,929 | 372 | $0.10 | $4,807 |
| J0897 Injection, denosumab, 1 mg | Office | 40,741 | 408 | $20.52 | $836K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 15,861 | 89 | $0.16 | $2,496 |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 15,077 | 25 | $33.87 | $511K |
| J9312 Injection, rituximab, 10 mg | Office | 11,401 | 31 | $60.75 | $693K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 8,831 | 39 | $24.73 | $218K |
| J0131 Injection, acetaminophen, not otherwise specified,10 mg | Office | 5,651 | 36 | $0.03 | $181 |
| 96401 Chemotherapy Administration | Office | 3,348 | 589 | $65.42 | $219K |
| 99214 Office E&M - Established | Office | 2,796 | 1,274 | $99.81 | $279K |
| 96372 Injection Administration | Office | 2,662 | 810 | $12.24 | $33K |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 2,100 | 261 | $0.51 | $1,062 |
By year: 2022 $7.6M for 519,400 services; 2023 $7.7M for 552,731 services; 2024 $8.7M for 705,420 services.
Medicare prescription drug claims, 2024
In 2024, the drug Shariar Cohen-Gadol prescribed most often to Medicare patients was Prednisone, with 596 prescriptions and refills. In total Shariar Cohen-Gadol wrote 6,598 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 596 | 1,197 | 217 | $6,549 |
| Celecoxib Generic | 431 | 742 | 156 | $18K |
| Gabapentin Generic | 339 | 629 | 96 | $6,571 |
| Hydroxychloroquine Sulfate Generic | 282 | 724 | 90 | $12K |
| Methotrexate Methotrexate Sodium | 256 | 602 | 75 | $6,781 |
| Methylprednisolone Generic | 169 | 211 | 105 | $2,187 |
| Pregabalin Generic | 163 | 278 | 42 | $3,450 |
| Allopurinol Generic | 152 | 428 | 52 | $1,524 |
| Mounjaro Tirzepatide | 149 | 162 | 24 | $166K |
| Tizanidine Hcl Generic | 144 | 297 | 62 | $1,812 |
| Duloxetine Hcl Generic | 137 | 322 | 48 | $4,647 |
| Meloxicam Generic | 124 | 260 | 53 | $788 |
| Diclofenac Sodium Generic | 123 | 205 | 43 | $7,779 |
| Tramadol Hcl Generic | 94 | 102 | 30 | $699 |
| Ibuprofen Generic | 90 | 163 | 34 | $827 |
Brand drugs: 1,138 claims; generic drugs: 5,380 claims; opioid claims: 233.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shariar Cohen-Gadol $12K ($12K in general payments such as food, travel and fees and $17.99 for research) from 30 companies. The largest payer was Amgen Inc. with $7,361.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 100 | $7,361 |
| Abbvie Inc. ABBV | 66 | $1,451 |
| UCB, Inc. UCB.BR | 28 | $898 |
| Novartis Pharmaceuticals Corporation NVS | 42 | $417 |
| GlaxoSmithKline, LLC. GSK | 12 | $263 |
| ANI Pharmaceuticals, Inc. ANIP | 9 | $211 |
| Radius Health, Inc. | 7 | $190 |
| Mallinckrodt Hospital Products Inc. | 5 | $156 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $132 |
| Vertex Pharmaceuticals Incorporated VRTX | 3 | $91.52 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.